Vioxx Recall

Merck & Co., Inc. announced a voluntary withdrawal of Vioxx (rofecoxib) from the U.S. and worldwide market due to safety concerns of an increased risk of cardiovascular events (including heart attack and stroke) in patients on Vioxx. Vioxx is a prescription COX-2 selective, non-steroidal anti-inflammatory drug (NSAID) that was approved by FDA in May 1999 for the relief of the signs and symptoms of osteoarthritis, for the management of acute pain in adults, and for the treatment of menstrual symptoms, and was later approved for the relief of the signs and symptoms of rheumatoid arthritis in adults and children.

Vioxx Recall News

November 4, 2004 - Vioxx withdrawal could cost Merck billions

Disclaimer: The information contained in this website does not constitute legal advice. We make no promises, claims or guarantees about the completeness, accuracy, or adequacy of the information contained in or linked to this web site and websites it we link to. Legal advice is specific to each case, current laws and must be addressed by an experienced lawyer.

Trademark Notice: "Vioxx" is a registered trademark of Merck. VioxxLawsuits.info is in no way affiliated with Merck, and the Vioxx trademark is used solely for informational purposes.